What we do

Lab21 Healthcare Ltd develops and supplies molecular diagnostic products to aid rapid and accurate diagnosis of life-threatening invasive fungal infections.

Traditional methods for the detection of fungal pathogens, such as culture and microscopy, are well-documented as being relatively insensitive and slow. Lab21 Myconostica assays use advances in molecular techniques, such as Real-Time PCR, to develop a range of assays for the rapid, accurate and sensitive detection of fungi such as Aspergillus spp. and Pneumocystis jirovecii.

Evidence shows that an early diagnosis of invasive fungal infection significantly improves the chance of survival. Tests provided by Lab21 aim to allow healthcare professionals to rapidly identify those patients infected by invasive fungal pathogens thus enabling clinicians to prescribe appropriate drug therapy. Early identification of disease reduces the patient’s exposure to inappropriate drug treatments, improves patient outcomes and reduces the hospitalisation and treatment costs associated with invasive fungal disease.